Buy Semaglutide Research Peptide
What Is Semaglutide?
Semaglutide is a synthetic, long-acting GLP-1 receptor agonist studied in metabolic and receptor-signaling research. It is a modified analogue of human GLP-1 with structural changes that support prolonged activity. Researchers use semaglutide as a model compound when examining GLP-1 receptor signaling and related metabolic pathways.
Vital Tides Peptides supplies semaglutide research material in 5 mg, 10 mg, and 20 mg vial options. Each product is intended for qualified laboratory and analytical research only.
Semaglutide (NN9535) has been characterized extensively in the published literature as a long-acting GLP-1R agonist. This research material is not a drug product.
Research use only. This product is not intended for human or veterinary use, diagnosis, treatment, or prevention of disease.
Learn more about semaglutide research, its mechanism of action, and current research status.
Semaglutide Compound Information
| Attribute | Vital Tides Peptides product information |
| Compound name | Semaglutide |
| Research identifier | Semaglutide; NN9535; NNC 0113-0217 |
| CAS number | 910463-68-2 |
| Compound class | Modified GLP- 1 Receptor Agonist Peptide |
| Research targets | GLP- 1 Receptor (GLP-1R) |
| Available sizes | 5 mg, 10 mg, and 20 mg |
| Product form | Lyophilized research material |
| Intended use | Controlled laboratory research only |
| Regulatory status | Not FDA-approved; research material only |
Mechanism of action
Semaglutide is designed to act as an agonist at the GLP-1 receptor (GLP-1R). Researchers may examine:
- GLP-1 receptor signaling
Activates GLP-1R signaling pathways involved in glucose-dependent cellular responses, pancreatic signaling, and metabolic regulation.
- Pancreatic & glucose-response signaling
Supports research into glucose-dependent insulin signaling and the interaction between GLP-1 receptor activity and pancreatic beta-cell pathways.
- Gastrointestinal signaling
Provides a research model for studying GLP-1-related pathways associated with gastric motility and post-meal signaling.
- Food-intake & energy-balance signaling
Allows researchers to investigate GLP-1 receptor signaling in central and peripheral models related to food intake, satiety, and energy balance. Research note: These mechanisms describe biological pathways associated with GLP-1 receptor research. They are not consumer benefits, treatment claims, or evidence that Vital Tides semaglutide research material is safe or effective for human use.
Research Applications & Areas of Interest
The Vital Tides Peptides semaglutide research peptide is studied in non-clinical research involving GLP-1 receptor signaling and metabolic regulation. As a selective GLP-1 receptor agonist, semaglutide provides a research model for examining how GLP-1R activation influences pancreatic, gastrointestinal, and central signaling pathways.
GLP-1 Receptor Research
Semaglutide may be used as a research compound to investigate:
- GLP-1 receptor activation and signaling
- Receptor-ligand interactions
- GLP-1R-mediated intracellular signaling
- Receptor selectivity and pharmacological activity
- Cellular responses to GLP-1 receptor stimulation
Glucose & Pancreatic Signaling Research
Semaglutide is relevant to research examining the relationship between GLP-1 receptor activation and pancreatic signaling. Researchers may study:
- Glucose-dependent insulin signaling
- Pancreatic beta-cell responses
- Insulin secretion pathways
- Glucagon-related signaling
- GLP-1-mediated metabolic responses
Gastrointestinal Signaling Research
GLP-1 signaling is also studied in relation to gastric motility and food-intake signaling. Semaglutide may therefore be examined in controlled models involving:
- Gastric emptying and gastrointestinal signaling
- Post-meal metabolic responses
- Food-intake signaling
- Satiety-related pathways
- Central pathways associated with energy balance
Metabolic Signaling Research
As a metabolic research peptide, semaglutide can support laboratory studies investigating interactions between GLP-1 receptor activity and broader metabolic pathways, including:
- Glucose homeostasis
- Insulin and glucagon signaling
- Nutrient-response pathways
- Energy-balance signaling
- GLP-1-related metabolic regulation
Research note: These topics describe in-vitro, animal, and other non-clinical research. They are not consumer benefits, treatment claims, or evidence that this product is safe or effective for human use.
Quality You Can Verify
Current Semaglutide 5 mg Sample
| Sample detail | Reported information |
| Sample ID | 9JJP-GRFW |
| Submitted product | Semaglutide 5 mg, one vial |
| COA publication date | June 17, 2026 |
| Testing source | Independent laboratory report |
Full QC Panel
| QC measurement | Reported result |
| Assay | 6.14 mg |
| Purity | 99.62% |
| Identity by retention time | 1.01, as reported |
| Identity by spectral analysis | 1000, as reported |
| Coelution control | 1000, as reported |
| System suitability | 0.9% RSD |
The results above apply to submitted sample 9JJP-GRFW.




Reviews
There are no reviews yet.